IDEAYA Biosciences (IDYA) vs Immunome (IMNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunome (IMNM) has outperformed IDEAYA Biosciences (IDYA) over the past year, gaining 37.8% versus a gain of 34.4%. Over five years, IDYA leads with a +55.9% price change compared with +9.7% for IMNM. IDEAYA Biosciences is the larger company by market cap ($3.48 billion vs $2.28 billion), about 1.5 times the size.
IDEAYA Biosciences converts more of its revenue into profit, with a net margin of -52.0% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDYA | IMNM |
|---|---|---|
| Share price | $36.06 | $19.31 |
| Market cap | $3.48B | $2.28B |
| 1-day change | -0.55% | +1.13% |
| YTD return | +4.31% | -10.10% |
| 1-year return | +34.35% | +37.83% |
| 5-year return | +55.90% | +9.65% |
| EPS (TTM) | $-1.94 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $218.71M | $6.94M |
| Revenue growth (YoY) | +3024.43% | -23.23% |
| Net income (latest FY) | $-113.70M | $-212.39M |
| Operating margin | -72.84% | -3228.83% |
| Net margin | -51.99% | -3059.99% |
| 52-week high | $42.68 | $30.06 |
| 52-week low | $26.05 | $13.49 |
| Distance from 52-week high | -15.51% | -35.76% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +46.28% | +82.29% |
| Average volume | 779.15K | 1.20M |
| Shares outstanding | 96.49M | 118.00M |
| Employees | 145 | 247 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDEAYA Biosciences is more profitable, keeping -52.0 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs -23.23%).
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
IDYA vs IMNM FAQ
Which is bigger, IDEAYA Biosciences or Immunome?
IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $3.48B compared with $2.28B for Immunome (IMNM).
Which stock has performed better over the past year, IDYA or IMNM?
IMNM returned +37.83% over the past 12 months, compared with +34.35% for IDYA (price return, excluding dividends). Past performance does not predict future results.
Are IDEAYA Biosciences and Immunome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.